An automated solid-phase extraction procedure combined with gas chromatography-mass spectrometry methodology, without derivatization, has been developed for the identification and quantitation of ketamine, norketamine, tramadol, methadone, 2-ethylidene-l,5-dimethyl-3,3~ and 2-ethyl-5-methyl-3,3-diphenylpyrroline in urine. The analytical approach is simple and rapid, yet reliable. Good linearity (r a > 0.995 over the concentration range of 30 to 600 ng/mL), sensitivity (limits of quantitation 15-30 ng/mL), accuracy (81.0-109.9%), precision (RSD < 13.8%), and recovery (> 79.6% in average) were achieved for all analytes. Ninety-one urine specimens from suspected drug users and 21 clinical urine specimens from methadone substitution therapy patients were analyzed to validate the method compatibility and stability. Results have demonstrated that this GC-MS method is a good confirmation and quantitation test scheme for the six target compounds in urine.
Introduction
Drugs-of-abuse monitoring projects on high-risk groups in Taiwan have been implemented by National Bureau of Controlled Drugs (NBCD), Department of Health, since 2002. Ketamine, tramadol, and methadone were found to be the three most prevalent drugs after heroin and methamphetamine (1) . In addition, harm reduction programs for heroin-dependent subjects have been available in Taiwan since 2005. Methadone substitution therapy is part of the program that catered to a total of 6866 heroin abusers in 43 hospitals at the end of July 2007. A good analytical method was thus needed for urine tests of these drugs.
Ketamine, one of the most widely used club drugs and a parenterally administered anesthetic agent, exhibits analgesic, amnestic, and sedative properties (2) . Ketamine is structurally and pharmacologically related to phencyclidine and is capable * Author to whom correspondence should be addressed. E-mail: chiareiyliu@nbcd.gov.tw.
of producing some of the same hallucinogenic side effects. Norketamine is its main metabolite by N-demethylation, exhibiting depressant effects similar to those of ketamine (3) . Tramadol is a synthetic opioid-receptor agonist that has been used clinically as a narcotic analgesic since 1977; it is used as an alternative to codeine and considered to cause less respiratory depression. For a single oral dose of tramadol, 90% is eliminated in urine and 10% in feces over a three-day period. The urine contains approximately 29% of the dose as unchanged drug and 20% as desmethyltramadol in a 72 h period (3) . Parenterally administered methadone possesses similar pharmacologic properties of morphine and is approximately equivalent in analgesic effect. Methadone causes respiratory depression, stupor, hypotension, and circulatory problems. It is metabolized by mono-and di-N-demethylation with spontaneous cyclization to form 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP). In subjects on methadone maintenance treatment, approximately 20-60% of a dose is excreted in urine in 24 h, with up to 33% of the dose as unchanged drug, up to 43% as EDDP, and EMDP accounts for 5-10%, with large individual variations due to pH, urine volume, dose, and metabolic rate (3, 4) .
Ketamine and its metabolites have been measured in urine specimens by gas chromatography-mass spectrometry (GC-MS) after liquid-liquid extraction (5,6), solid-phase extraction (SPE) (7-9), or headspace solid-phase microextraction (10) . To the best of our knowledge, only one GC-MS study has been performed for determination of tramadol in urine (11) , others were concerned with tramadol quantitation in plasma (12) or in hair (10) . The validation data such as sensitivity, accuracy, and precision for the quantitation of tramadol in urine is still insufficient. Various research has reported on the determination of methadone and its metabolites in urine by GC-MS methods (10, 11, (13) (14) (15) (16) (17) . However, there is no GC-MS method with complete validation for the simultaneous determination of ketamine, tramadol, methadone, and their metabolites in urine.
Confronting the abuse problems with ketamine and tramadol, as well as the increase in methadone use for substitu-tion treatment, this study has developed and validated a GC-MS method that determines these drugs and their main metabolites norketamine, EDDP, and EMDP in urine for the purpose of confirmation and quantitation. This method has been successfully applied to urine specimens from suspected drug users and methadone substitution therapy patients. Furthermore, the GC-MS method established in this study achieved better sensitivity and reduced analytical time and cost by eliminating the derivatization step.
Experimental

Materials
Ketamine hydrochloride, ketamine-d4 hydrochloride, norketamine hydrochloride, norketamine-d4 hydrochloride, cistramadol hydrochloride, methadone, methadone-dg, EDDP perchlorate, EDDP-d3 perchlorate, and EMDP were purchased from Cerilliant (Austin, TX). HPLC-grade methanol and dichloromethane were purchased from Merck (Darmstadt, Germany). Ethyl acetate, isopropanol, acetic acid, and ammonium hydroxide were purchased from ACROS (Morris Plains, N J). Ultra-pure water was produced with a Milli-Q purification system from Millipore (Bedford, MA). SPEC DAU SPE cartridges (3 mL) were purchased from Varian (Palo Alto, CA).
Standard stock solutions of all analytes (100 I~g/mL) were prepared in ethanol and stored at -20~ Working standard solutions and internal standard solutions for calibration and quality control, respectively, were prepared in ethanol (10 l~g/mL in each) and stored at 4~ Acetate buffer was prepared by dissolving 2.93 g sodium acetate and 1.62 mL glacial acetic acid in 500 mL ultra-pure water, adjusted to pH 4.5 by sodium acetate or glacial acetic acid, and then kept at room temperature. The rinse solution (70% methanol) and eluent solution (80:20:2, dichloromethane/isopropanol/ammonium hydroxide) for SPE were prepared daily. nationwide and collected by law enforcement agencies from suspected drug users during January 2005. In addition, 21 clinical urine specimens sampled from patients on methadone substitution therapy were generously provided by Taoyuan Mental Hospital. The six calibrators contained 30, 60, 100, 200, 400, and 600 ng/mL of ketamine, norketamine, tramadol, methadone, EDDP, and EMDP, respectively, and 100 ng/mL of ketamine-d4, norketamine-d4, methadone-d9, and EDDP-d3. Quality controis contained 45, 150, and 500 ng/mL of the analytes as the low, medium, and high level controls, respectively. They were prepared by separately adding designated amounts of the working standard solution into 2 mL drug-free urine.
Ketamine-d4, norketamine-d4, methadone-dg, and EDDPd3 were used as the internal standards for the quantitation of ketamine, norketamine, methadone, and EDDP, respectively. EDDP-d3 was also used as the internal standard for tramadol and EMDP quantitation for lack of deuterated EMDP. Test specimens (2 mL), calibrators, and controls were first spiked with 20 pL internal standard solution, and then acidified with 2 mL acetate buffer and vortex mixed. Extraction proceeded with SPEC DAU SPE cartridges on a Zymark automated SPE system (Hopkinton, MA). The cartridge was first conditioned with 0.8 mL methanol, followed by 0.8 mL ultra-pure water, and then 0.8 mL acetate buffer. After loading the sample, the cartridge was washed with I mL acetate buffer, followed by 0.7 mL ultra-pure water, and then nitrogen-purged for 0.4 min. The cartridge was washed again with 1 mL rinse solution. Analytes retained were subsequently eluted with 1 mL eluent solution following a 0.2 rain nitrogen purge. The eluate was evaporated to dryness at 40~ under a nitrogen stream and reconstituted with 100 pL ethyl acetate prior to GC-MS analysis.
GC-MS confirmation
An Agilent 6890 GC/5973 MSD system was adopted in this study using a HP-5MS column (30 m x 0.25-mm i.d., 0.25-1Jm film thickness). GC oven temperature was programmed to rise initially from 130~ to 170~ at 10~ to 200~ at 5~ and then to 250~ at 10~ A 2-1JL aliquot was injected in splitless mode. The injection port and transfer line temperatures were set at 260~ and 280~ respectively. Helium was used as the carrier gas at a constant flow rate of 1 mL/min. The MS was operated in electronic impact (EI) mode, and selected ion monitoring (SIM) mode was used for identification and quantitation.
Results and Discussion
Optimization and validation of GC-MS method
Ion selection for SIAlmode. Full scan mass spectra of all analytes and internal standards were obtained (Figure 1 ). The five most intense ions of each analyte were chosen for the crosscontribution evaluation under SIM mode. Table I shows the SIM response and cross-contribution of selected ions between peak-overlapped analytes in total ion chromatogram. There were at least three ions with high relative abundance, and low cross-contribution (< 5%) could be chosen for each target compound. Methadone-d3 and methadone-d9 were compared to serve as methadone internal standard, and methadone-d9 was selected because methadone-d3 produced intense fragment ion m/z 72 (the same as methadone) making qualification and quantitation difficult. 13C-Tramadol-d3 was initially evaluated as internal standard for tramadol, but critical crosscontribution from tramadol and EMDP resulted in inadequate ions that were selectable for 13C-tramadol-d3. EDDP-d3 was consequently selected as the internal standard for tramadol. Besides, during the GC-MS method development, GC-MS showed poor sensitivity to desmethyltramadol (data not shown here), and desmethyltramadol was consequently not included. The cross-contribution evaluation data of ketamine, ketamined4, norketamine, and norketamine-d4 has been discussed previously (9) using the same GC oven temperature program (0 to 10 min), and the selected ions for these four compounds were followed by this method. Retention times and ions selected for the 10 compounds for this GC-MS analysis are listed in Table  II . Three qualification ions were selected for each of the six analytes, whereas two were selected for each of the four internal standards. Figure 2 shows the total ion chromatograms derived from drug-free urine spiked with 20 ng/mL of each analyte (A), and from blank urine (B). The total run time was 15 rain, which is faster than previously published GC-MS methods for ketamine (5, 7, 8, 10) , tramadol (10, 11) , and methadone (10,11) determination in urine. Compared to ketamine derivatization with TFAA (6) or MBTFA (8) prior to GC-MS analysis, this method is simple, fast, and more cost-effective.
Linearity, limit of detection, and limit of quantitation. Calibration curves within the 30-600 ng/mL range were linear for ketamine, norketamine, tramadol, methadone, EDDP, and EMDP (R 2 = 0.999, 0.999, 0.995, 1.000, 1.000, and 0.996, respectively). Table III shows the limit of detection (LOD), limit of quantitation (LOQ), and root mean square (RMS) signal-tonoise (S/N) of each analyte. LOD was defined as the lowest concentration at which all replicates had qualification ion ratios within • 20% of the expected value. LODs were determined by analyzing a series of spiked urine samples (n = 3) with decreasing analyte concentrations and were lower than 20 ng/mL for the six analytes. LOQ was determined using the same criteria as LOD, while the quantitative results must be within _+ 20% of the expected value. LOQs for the six analytes were all lower than 30 ng/mL. The LOD and LOQ definitions were more critical than using multiple S/N ratios as the limits, which was generally adopted by chromatographic methodology. Moreover, these demanding definitions make drug confirmation test results more reliable and conformed to forensic applications. The lowest concentration of spiked urine samples tested in this study was 1 ng/mL, at this concentration, the RMS S/N of norketamine, ketamine, tramadol, EMDP, EDDP, and methadone were 61, 101, 45, 79, 127, and 37, respectively. The high S/N obtained at very low analyte concentration (1 ng/mL) showed that this analytical approach is more sensitive than previously published quantitation methods for ketamine (5-9), tramadol (11), methadone (11, 14, 16, 18) , and their metabolites in urine. Accuracy, precision, and recovery. Accuracy, precision, and recovery of the six analytes are listed in Table IV . Intraday accuracy ranged between 81.0 and 109.9%. Intraday precision ranged between 0.7 and 7.4% (except EMDP at 45 ng/mL). Interday accuracy ranged between 92.2 and 104.0%. Interday precision ranged between 1.5 and 12.2%. Extraction recovery of the analytes was determined by comparing the response ratios (analyte/internal standard) between two sets of control samples. The internal standard was spiked to every sample before SPE. For recovery study, standard solution contained all analytes was spiked to a set of three different concentrations before extraction, and to the other set after extraction. Recovery was calculated by dividing the response ratios of the two sets. The average recovery for all analytes was over 79%. The high average recovery of tramadol (110.7%) was probably due to physical property differences between tramadol and EDDP and the use of EDDP-d 3 but not 13C-tramadol-d3 as the internal standard. These results show that this method is accurate and precise with good recovery through the linear quantitation range.
Evaluation of GC-MS method with clinical specimens
Urine specimens from suspected drug users. Ketamine, nor- Table Ill Ketamine  101  15  15  Tramadol  45  20  30  s  79  20  30  EDDP  127  20  20  Methadone  37  5  20 ketamine, tramadol, methadone, EDDP, and EMDP in 91 urine specimens from the NBCD drug monitoring project were analyzed to evaluate the method performance. Ketamine, tramadol, methadone, and EDDP in these urine specimens were first screened by REMEDi and enzyme immunoassay (data not shown here). Specimens with screened concentrations over the linearity range of this method were appropriately diluted for GC-MS quantitation. Test results of 14 urine specimens were positive and are listed in Table V . A urine specimen was considered positive if any concentration of the six analytes was higher than its LOQ. Ketamine, norketamine, and tramadol were detected in 7, 8, and 6 urine specimens, respectively. However, no specimen was positive for methadone, EDDP, or EMDP in these 91 specimens. Ketamine and norketamine concentrations showed wide variation in comparison with those of tramadoL The concentration range of ketamine was between 21 and 5620 ng/mL (1486 ng/mL in average), the concentration range of norketamine was the widest (66-9031 ng/mL) with an average 2263 ng/mL, and the concentration range of tramadol was the narrowest (226-3081 ng/mL) with an average 1064 ng/mL. Accuracy zo ="E x 100%
t Precision (%) = S_._ x 100% xo Xn = average, n = number of replicates. S = standard deviation, C = spiked concentration.
Norketamine concentration was higher than ketamine concentration in every one of the eight positive urine specimens; this was possibly due to fewer positive specimens obtained in this study. These findings were in agreement with the conclusions of our previous report (9) . Urine specimens from methadone substitution therapy patients. As methadone substitution therapy has been used to treat opiate dependence, monitoring the levels of methadone and its metabolites in biological fluids such as urine provides useful information on the pharmacokinetics. The concentration information allows physicians to adjust proper dosage to meet the patients' needs and ensures that the patients are taking methadone on schedule (15, 19, 20) . An application test was performed to analyze methadone, EDDP, and EMDP in 21 clinical urine specimens from methadone substitution therapy patients to evaluate the performance of this GC-MS method. Methadone and EDDP in these clinical urine specimens were first screened by enzyme immunoassay (data not shown here), specimens with screening concentrations over the linearity range of this method were appropriately diluted for GC-MS quantitation. The GC-MS test results are listed in Table VI .
Methadone and EDDP, but not EMDP, were detected in the 21 urine specimens from methadone substitution therapy subjects. This result indicated that EMDP concentration in these urine specimens was lower than the LOQ. In urine studies by Sullivan and Due (21) and Alburges et al. (14) , EMDP concentrations were also reported significantly lower than either methadone or EDDP concentrations. Numerous studies have researched the metabolism of methadone. Methadone is predominantly N-demethylated and undergoes spontaneous cyclization to produce EDDP, which is subsequently Ndemethylated to EMDP at low formation rate (22) (23) (24) . The low EMDP amount in urine was probably because the dosed methadone had been excreted as unchanged drug and EDDP before it was subsequently metabolized to EMDP. 
Methadone EDDP EDDP/Methadone
However, we have neither the dose of methadone nor the timing of urine collection for the specimens we quantified. It is difficult to further discuss the relation between dosage and metabolite levels in a pharmacokinetic manner. As methadone and EDDP exist in almost all urine specimens from methadone substitution therapy patients, simultaneous determination of methadone and its metabolite EDDP by this GC-MS method can be used to monitor whether these patients are taking methadone on schedule.
Conclusions
A sensitive, applicable, and reliable GC-MS method for ketamine, norketamine, tramadol, methadone, EDDP, and EMDP quantitation in urine has been developed. Good linearity, LOD, LOQ, accuracy, precision, and recovery were demonstrated. This new method has been successfully applied to 91 urine specimens from suspected drug users and 21 clinical urine specimens from methadone substitution therapy patients. Good agreement between urine specimen analysis results of this study and the previous studies was observed. EDDP should be the target analyte of choice for methadone users, because methadone and EDDP were both present in most urine specimens, with EDDP at higher concentrations. This validated method is suitable for routine, clinical, epidemiological, and forensic applications and may be applied to other biological samples.
